Long-term follow-up of psilocybin-facilitated smoking cessation

A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone.

To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration.